Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 3/20 | 0.44 |
| ▸ | BCR | P11274 | 3/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.44 |
| ▸ | PRKCA | P17252 | 1/20 | 0.44 |
| ▸ | TEK | Q02763 | 2/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | STAT3 | P40763 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7235236 | 0.91 | EPHX2 (0.52) | EPHX2MAPTABL1BCRPDGFRB | |
| SCHEMBL5205222 | 0.87 | EPHX2 (0.48) | EPHX2MAPTNPC1RAB9AABL1 | |
| SCHEMBL7635971 | 0.86 | MAPT (0.46) | EPHX2MAPTNPC1RAB9AABL1 | |
| SCHEMBL7233535 | 0.85 | CACNA1B (0.42) | EPHX2MAPT | |
| SCHEMBL7239115 | 0.83 | MAPT (0.46) | MAPTNPC1RAB9AABL1BCR | |
| SCHEMBL7240172 | 0.79 | EPHX2 (0.48) | EPHX2MAPTABL1BCRPDGFRB | |
| SCHEMBL7232820 | 0.78 | ALDH1A1 (0.39) | EPHX2MAPTCYP11B1CYP11B2 | |
| SCHEMBL7243695 | 0.74 | EPHX2 (0.51) | EPHX2LMNA | |
| SCHEMBL7631313 | 0.74 | MAPT (0.45) | EPHX2MAPTNPC1RAB9AABL1 | |
| SCHEMBL6986838 | 0.74 | CNR2 (0.45) | MAPTNPC1RAB9ALMNASTAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1406892-B1 | PHENYL PYRAZOLE DERIVATIVES AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (US) | 2007-09-05 | — | — | EP | claimed |
| US-6890925-B2 | Methods of using soluble epoxide hydrolase inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-05-10 | — | — | US | claimed |
| US-20040092567-A1 | Methods of using soluble epoxide hydrolase inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC | 2004-05-13 | — | — | US | claimed |
| EP-1406892-A1 | PHENYL PYRAZOLE DERIVATIVES AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-04-14 | — | — | EP | claimed |
| US-20030022929-A1 | Method of using soluble epoxide hydrolase inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-01-30 | — | — | US | claimed |
| US-6506747-B1 | Method of treating an inflammatory disease which comprises administering to a patient in need of such treatment-a N-(4-(5-Ethyl-3-pyridin-3-yl-pyrazol-1-yl)phenyl)pyridine-3-carboxamide; | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-01-14 | — | — | US | claimed |
| WO-2003002555-A1 | METHODS OF USING SOLUBLE EPOXIDE HYDROLASE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2003-01-09 | — | — | WO | claimed |
| JP-2002516909-A | — | — | 2002-06-11 | — | — | JP | claimed |
| WO-2000023060-A2 | METHOD OF TREATING IMMUNOLOGICAL DISORDERS MEDIATED BY T-LYMPHOCYTES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2000-04-27 | — | — | WO | claimed |
| WO-1999062885-A1 | SUBSTITUTED 1-(4-AMINOPHENYL)PYRAZOLES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1999-12-09 | — | — | WO | claimed |
| EP-1406892-B1 | PHENYL PYRAZOLE DERIVATIVES AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (US) | 2007-09-05 | — | — | EP | disclosed |
| US-6890925-B2 | Methods of using soluble epoxide hydrolase inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-05-10 | — | — | US | disclosed |
| US-6831082-B2 | 1-phenyl pyrazole derivatives; treating cardiovascular disease | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-12-14 | — | — | US | disclosed |
| US-20040092567-A1 | Methods of using soluble epoxide hydrolase inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC | 2004-05-13 | — | — | US | disclosed |
| EP-1406892-A1 | PHENYL PYRAZOLE DERIVATIVES AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-04-14 | — | — | EP | disclosed |
| US-20030022929-A1 | Method of using soluble epoxide hydrolase inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-01-30 | — | — | US | disclosed |
| US-6506747-B1 | Method of treating an inflammatory disease which comprises administering to a patient in need of such treatment-a N-(4-(5-Ethyl-3-pyridin-3-yl-pyrazol-1-yl)phenyl)pyridine-3-carboxamide; | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-01-14 | — | — | US | disclosed |
| WO-2003002555-A1 | METHODS OF USING SOLUBLE EPOXIDE HYDROLASE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2003-01-09 | — | — | WO | disclosed |
| WO-1999062885-A1 | SUBSTITUTED 1-(4-AMINOPHENYL)PYRAZOLES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1999-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022929-A1 | Method of using soluble epoxide hydrolase inhibitors | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885MAPT 4786/4885NPC1 838/4885 |
| US-20040092567-A1 | Methods of using soluble epoxide hydrolase inhibitors | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885MAPT 4771/4885NPC1 1092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.